Calcipotriol/Betamethasone Dipropionate: A Review of its Use in the Treatment of Psoriasis Vulgaris

Authors: Caroline Fenton; Greg L. Plosker

Source: American Journal of Clinical Dermatology, Volume 5, Number 6, 2004 , pp. 463-478(16)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

The two-compound product containing calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet^®, Daivobet^®) [referred to here as calcipotriol/betamethasone dipropionate], is a topical treatment for psoriasis vulgaris, combining a vitamin D analog and a corticosteroid.

For most adult patients with psoriasis vulgaris on the trunk and limbs, up to 4 weeks of therapy with calcipotriol/betamethasone dipropionate provides an effective and well tolerated treatment. In clinical trials, patients with a mean baseline psoriasis area and severity index (PASI) of 9.5–10.9 experienced a mean 65.0–74.4% PASI improvement within 4 weeks, significantly better than improvements with calcipotriol 50 µg/g monotherapy, betamethasone dipropionate 0.5 mg/g monotherapy, or placebo. In addition, in 6.4%–20.1% of patients, lesions cleared. In patients who were subsequently treated with calcipotriol maintenance therapy, benefits were retained for at least 4 weeks. The safety of calcipotriol/betamethasone dipropionate in patients treated for up to 1 year was generally good; fewer than 5% of patients experienced adverse events possibly associated with long-term corticosteroid use.

Keywords: Adis Drug Evaluations; Calcipotriol/betamethasone dipropionate, general; Psoriasis, treatment

Document Type: Research article

Affiliations: 1: Adis International Limited, Yardley, Pennsylvania, USA

Publication date: 2004-01-01